Ultomiris Helps Ease gMG Symptoms in Ongoing Phase 3 Trial

Ultomiris Helps Ease gMG Symptoms in Ongoing Phase 3 Trial

299987

Ultomiris Helps Ease gMG Symptoms in Ongoing Phase 3 Trial

Ultomiris (ravulizumab-cwvz) rapidly and sustainably eased symptom severity in adults with generalized myasthenia gravis (gMG), according to top-line data from a Phase 3 trial. Alexion Pharmaceuticals, the therapy’s developer, now plans to submit regulatory applications requesting approval of Ultomiris for gMG in the U.S., Europe, and Japan, later this year and/or in early 2022. “These data provide confidence that Ultomiris has the potential to become the new standard of care for gMG,” John Orloff, MD,…

You must be logged in to read/download the full post.